Literature DB >> 33584540

Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases.

Keyi Zhang1, Xuefei Shou1, Hong Chen2, Nidan Qiao1, Wenqiang He1, Zhengyuan Chen1, Ming Shen1, Shiqi Li1, Yao Zhao1, Zhaoyun Zhang3, Yiming Li3, Hongying Ye3, Yongfei Wang1.   

Abstract

Purpose: To investigate the different clinical characteristics of silent corticotroph adenomas (SCAs) with positive and negative adrenocorticotropic hormone (ACTH) immunostaining, and to explore the value of pituitary-restricted transcription factor (Tpit) immunostaining for diagnosing SCAs.
Methods: The clinical materials of patients with SCAs who had a typical pathological feature with positive Tpit immunostaining and positive/negative ACTH immunostaining, and without clinical features and biochemical evidence for Cushing's Syndrome in our center from April 2018 to March 2019 were analyzed retrospectively. The differences in clinical characteristics and surgical results between ACTH-positive and -negative SCAs were explored.
Results: A total of one hundred and five patients (94.3% female) with SCAs were included. There were 66 SCAs with ACTH-negative (66/105, 62.9%), and 39 SCAs with ACTH-positive (39/105, 37.1%). Cases with ACTH-negative SCAs were more likely to have lower ACTH levels (27.5 ± 24.0 vs. 54.4 ± 58.6, P = 0.011), more multiple microcysts (81.8% vs. 61.5%, P = 0.022) and lower levels of Ki-67 expression (low expression rate 90.9% vs. 74.4%, P = 0.023). No statistical significant differences were observed between patients with ACTH-positive and -negative SCAs regarding gender (97.0% vs. 89.7%, P = 0.192), age (50.3 ± 10.3 vs. 49.0 ± 11.2, P = 0.543), surgical history (16.7% vs. 23.1%, P = 0.419), suprasellar extension (66.7% vs. 74.4%, P = 0.408), sphenoid sinus extension (51.5% vs. 56.4%, P = 0.627), cavernous sinus invasion (75.8% vs. 66.7%, P = 0.314), large cyst on Magnetic Resonance Imaging (MRI) (47.0% vs. 61.5%, P = 0.149), or gross total resection rate (42.4% vs. 51.3%, P = 0.379). Conclusions: ACTH-negative SCAs were observed to be more clinically silent and more likely to demonstrate multiple microcysts on MRI. The prevalence of SCAs, especially ACTH-negative SCAs, proved to be substantially underestimated and thus they should be given enough attention in consideration of the high aggressiveness of this subtype of refractory pituitary adenoma (PA).
Copyright © 2021 Zhang, Shou, Chen, Qiao, He, Chen, Shen, Li, Zhao, Zhang, Li, Ye and Wang.

Entities:  

Keywords:  Tpit immunostaining; non-functioning pituitary adenoma; pituitary incidentaloma; refractory pituitary adenoma; silent corticotroph adenoma

Mesh:

Substances:

Year:  2021        PMID: 33584540      PMCID: PMC7873875          DOI: 10.3389/fendo.2020.608691

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


  18 in total

1.  Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas.

Authors:  Adriana G Ioachimescu; Leslie Eiland; Vaninder S Chhabra; Gena M Mastrogianakis; Matthew J Schniederjan; Daniel Brat; Anthony V Pileggi; Nelson M Oyesiku
Journal:  Neurosurgery       Date:  2012-08       Impact factor: 4.654

2.  The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.

Authors:  Hiroshi Nishioka; Naoko Inoshita; Ozgur Mete; Sylvia L Asa; Kyohei Hayashi; Akira Takeshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Yasuhiro Takeuchi; Shozo Yamada
Journal:  Endocr Pathol       Date:  2015-12       Impact factor: 3.943

3.  Accuracy of microcystic aspect on T2-weighted MRI for the diagnosis of silent corticotroph adenomas.

Authors:  Leandro Kasuki; Ximene Antunes; Maria Caroline Alves Coelho; Elisa Baranski Lamback; Sarah Galvão; Aline Helen Silva Camacho; Leila Chimelli; Nina Ventura; Mônica R Gadelha
Journal:  Clin Endocrinol (Oxf)       Date:  2019-12-12       Impact factor: 3.478

4.  Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study.

Authors:  Or Cohen-Inbar; Zhiyuan Xu; Cheng-Chia Lee; Chin-Chun Wu; Tomáš Chytka; Danilo Silva; Mayur Sharma; Hesham Radwan; Inga S Grills; Brandon Nguyen; Zaid Siddiqui; David Mathieu; Christian Iorio-Morin; Amparo Wolf; Christopher P Cifarelli; Daniel T Cifarelli; L Dade Lunsford; Douglas Kondziolka; Jason P Sheehan
Journal:  J Neurooncol       Date:  2017-09-14       Impact factor: 4.130

5.  Clinical features of silent corticotroph adenomas.

Authors:  Hussein Alahmadi; Daniel Lee; Jefferson R Wilson; Caroline Hayhurst; Ozgur Mete; Fred Gentili; Sylvia L Asa; Gelareh Zadeh
Journal:  Acta Neurochir (Wien)       Date:  2012-05-24       Impact factor: 2.216

6.  Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas.

Authors:  Daham Kim; Cheol Ryong Ku; Se Hee Park; Ju Hyung Moon; Eui Hyun Kim; Sun Ho Kim; Eun Jig Lee
Journal:  World Neurosurg       Date:  2018-04-17       Impact factor: 2.104

7.  A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas.

Authors:  Arman Jahangiri; Jeffrey R Wagner; Melike Pekmezci; Anne Hiniker; Edward F Chang; Sandeep Kunwar; Lewis Blevins; Manish K Aghi
Journal:  Neurosurgery       Date:  2013-07       Impact factor: 4.654

8.  Defective expression of prohormone convertase 1/3 in silent corticotroph adenoma.

Authors:  Toru Tateno; Hajime Izumiyama; Masaru Doi; Takumi Akashi; Kikuo Ohno; Yukio Hirata
Journal:  Endocr J       Date:  2007-10-02       Impact factor: 2.349

9.  Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas.

Authors:  Hwa Young Cho; Sun Wook Cho; Sang Wan Kim; Chan Soo Shin; Kyong Soo Park; Seong Yeon Kim
Journal:  Clin Endocrinol (Oxf)       Date:  2009-07-24       Impact factor: 3.478

10.  Clinical Significance of Radical Surgery in the Treatment of Silent Corticotroph Adenoma.

Authors:  Junhyung Kim; Seon Jin Yoon; Ju Hyung Moon; Cheol Ryong Ku; Se Hoon Kim; Eun Jig Lee; Sun Ho Kim; Eui Hyun Kim
Journal:  J Korean Neurosurg Soc       Date:  2018-12-31
View more
  1 in total

Review 1.  An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.

Authors:  Shenzhong Jiang; Xiaokun Chen; Yinzi Wu; Renzhi Wang; Xinjie Bao
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.